Implications of COVID-19 in Parkinson’s disease: the purinergic system in a therapeutic-target perspective to diminish neurodegeneration
- 9 March 2024
- journal article
- review article
- Published by Springer Nature in Purinergic Signalling
- Vol. 20 (5) , 487-507
Abstract
The pathophysiology of Parkinson’s disease (PD) is marked by degeneration of dopaminergic neurons in the substantia nigra. With advent of COVID-19, which is closely associated with generalized inflammation and multiple organ dysfunctions, the PD patients may develop severe conditions of disease leading to exacerbated degeneration. This condition is caused by the excessive release of pro-inflammatory markers, called cytokine storm, that is capable of triggering neurodegenerative conditions by affecting the blood–brain barrier (BBB). A possible SARS-CoV-2 infection, in serious cases, may compromise the immune system by triggering a hyperstimulation of the neuroimmune response, similar to the pathological processes found in PD. From this perspective, the inflammatory scenario triggers oxidative stress and, consequently, cellular dysfunction in the nervous tissue. The P2X7R seems to be the key mediator of the neuroinflammatory process, as it acts by increasing the concentration of ATP, allowing the influx of Ca2+ and the occurrence of mutations in the α-synuclein protein, causing activation of this receptor. Thus, modulation of the purinergic system may have therapeutic potential on the effects of PD, as well as on the damage caused by inflammation of the BBB, which may be able to mitigate the neurodegeneration caused by diseases. Considering all the processes of neuroinflammation, oxidative stress, and mitochondrial dysfunction that PD propose, we can conclude that the P2X7 antagonist acts in the prevention of viral diseases, and it also controls purinergic receptors formed by multi-target compounds directed to self-amplification circuits and, therefore, may be a viable strategy to obtain the desired disease-modifying effect. Thus, purinergic system receptor modulations have a high therapeutic potential for neurodegenerative diseases such as PD.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (404256/2021-0)
This publication has 119 references indexed in Scilit:
- On the role of P2X7 receptors in dopamine nerve cell degeneration in a rat model of Parkinson’s disease: studies with the P2X7 receptor antagonist A-438079Journal of Neural Transmission, 2010
- Molecular and cellular mechanisms of excitotoxic neuronal deathApoptosis, 2010
- P2X7-Dependent Release of Interleukin-1β and Nociception in the Spinal Cord following LipopolysaccharideJournal of Neuroscience, 2010
- Amyloid-β Induces a Caspase-mediated Cleavage of P2X4 to Promote PurinotoxicityNeuroMolecular Medicine, 2009
- Neuroinflammation in Parkinson's disease: a target for neuroprotection?The Lancet Neurology, 2009
- Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascadeBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2008
- The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significancePurinergic Signalling, 2006
- Ectonucleotidases in the Nervous System2006
- Passage of Cytokines across the Blood-Brain BarrierNeuroimmunomodulation, 1995
- Is there a basis for distinguishing two types of P2-purinoceptor?General Pharmacology: The Vascular System, 1985